Ge Lihui, Wang Linlin, Pei Dongmei
Department of Health Management, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Department of Thoracic Surgery, Shenyang Tenth People's Hospital, Shenyang, Liaoning, China.
Heliyon. 2024 Mar 29;10(9):e28881. doi: 10.1016/j.heliyon.2024.e28881. eCollection 2024 May 15.
Pulmonary mucinous adenocarcinoma (PMA), a distinct subtype of non-small cell lung cancer (NSCLC), is characterized by an abundance of mucin-producing cells. Although this subtype comprises a relatively small fraction of lung adenocarcinomas, PMA stands apart due to its unique clinical, pathological, and molecular features. This review comprehensively discusses the pathophysiology and etiology, clinical features, diagnostic methods, treatment strategies, prognosis, and future directions for PMA, drawing from relevant literature and existing studies. Advances in PMA treatment includes surgical intervention, targeted therapy, immunotherapy, and adjuvant therapy. Particularly, we discussed factors influencing the prognosis of PMAs, such as molecular markers, pathological features, and the impact of the latest treatment advances on prognosis. Moreover, we intended this review to be a comprehensive reference for diagnosing, treating, and assessing the prognosis of PMA, providing valuable guidance for clinical practice.
肺黏液腺癌（PMA）是非小细胞肺癌（NSCLC）的一种独特亚型，其特征是有大量产生黏液的细胞。尽管该亚型在肺腺癌中所占比例相对较小，但PMA因其独特的临床、病理和分子特征而与众不同。本综述综合讨论了PMA的病理生理学和病因、临床特征、诊断方法、治疗策略、预后及未来方向，参考了相关文献和现有研究。PMA治疗的进展包括手术干预、靶向治疗、免疫治疗和辅助治疗。特别是，我们讨论了影响PMA预后的因素，如分子标志物、病理特征以及最新治疗进展对预后的影响。此外，我们希望本综述能成为诊断、治疗和评估PMA预后的全面参考，为临床实践提供有价值的指导。
